evidencegaps
Primary study · included by 1 review

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.

Liu 2022 · Liu Jun, Yang Yang, Liu Zhichao, et al. · Journal for immunotherapy of cancer · 2022

Included by

The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas.
Non-Cochrane · intervention · 2026 · cited as Liu 2022 · Supplementary Table S1; reference list

The review does not say which of its outcomes this study informs.

1 including review in total.